DURECT Corporation (DRRX)
USD 0.75
(3.5%)
USD 0.75
(3.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -36.88 Million USD | -5.14% |
| 2022 | -35.08 Million USD | -2.36% |
| 2021 | -34.27 Million USD | -171.68% |
| 2020 | -12.61 Million USD | 34.13% |
| 2019 | -19.15 Million USD | 18.92% |
| 2018 | -23.61 Million USD | -955.83% |
| 2017 | -2.23 Million USD | 93.09% |
| 2016 | -32.36 Million USD | -56.62% |
| 2015 | -20.66 Million USD | 1.59% |
| 2014 | -20.99 Million USD | 0.77% |
| 2013 | -21.16 Million USD | -231.8% |
| 2012 | 16.05 Million USD | 185.16% |
| 2011 | -18.85 Million USD | 20.9% |
| 2010 | -23.83 Million USD | 23.36% |
| 2009 | -31.09 Million USD | 32.11% |
| 2008 | -45.8 Million USD | -86.66% |
| 2007 | -24.54 Million USD | 21.93% |
| 2006 | -31.43 Million USD | -101.15% |
| 2005 | -15.62 Million USD | 35.71% |
| 2004 | -24.3 Million USD | -14.24% |
| 2003 | -21.27 Million USD | 45.4% |
| 2002 | -38.96 Million USD | 21.12% |
| 2001 | -49.4 Million USD | -116.46% |
| 2000 | -22.82 Million USD | -143.86% |
| 1999 | -9.35 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.71 Million USD | 8.59% |
| 2024 Q2 | -3.4 Million USD | 40.46% |
| 2023 Q2 | -10.05 Million USD | 8.81% |
| 2023 Q1 | -11.02 Million USD | 4.14% |
| 2023 Q3 | -9.55 Million USD | 4.91% |
| 2023 Q4 | -6.25 Million USD | 34.56% |
| 2023 FY | -36.88 Million USD | -5.14% |
| 2022 Q2 | -11.08 Million USD | -6.95% |
| 2022 FY | -35.08 Million USD | -2.36% |
| 2022 Q3 | -2.13 Million USD | 80.77% |
| 2022 Q4 | -11.49 Million USD | -439.31% |
| 2022 Q1 | -10.36 Million USD | -59.18% |
| 2021 Q2 | -8.65 Million USD | 10.25% |
| 2021 Q4 | -6.51 Million USD | 31.15% |
| 2021 Q1 | -9.64 Million USD | -16.13% |
| 2021 FY | -34.27 Million USD | -171.68% |
| 2021 Q3 | -9.45 Million USD | -9.25% |
| 2020 Q3 | -8.87 Million USD | -160.12% |
| 2020 Q4 | -8.3 Million USD | 6.36% |
| 2020 Q1 | -9.61 Million USD | -142.78% |
| 2020 FY | -12.61 Million USD | 34.13% |
| 2020 Q2 | 14.75 Million USD | 253.47% |
| 2019 Q1 | -6.71 Million USD | 2.64% |
| 2019 Q3 | -1.71 Million USD | 74.73% |
| 2019 Q2 | -6.77 Million USD | -0.89% |
| 2019 FY | -19.15 Million USD | 18.92% |
| 2019 Q4 | -3.96 Million USD | -131.44% |
| 2018 Q4 | -6.89 Million USD | -201.22% |
| 2018 FY | -23.61 Million USD | -955.83% |
| 2018 Q3 | -2.28 Million USD | 65.37% |
| 2018 Q2 | -6.6 Million USD | 15.64% |
| 2018 Q1 | -7.83 Million USD | -191.39% |
| 2017 Q4 | 8.57 Million USD | 39.92% |
| 2017 FY | -2.23 Million USD | 93.09% |
| 2017 Q1 | -7.56 Million USD | 8.41% |
| 2017 Q2 | -9.36 Million USD | -23.76% |
| 2017 Q3 | 6.12 Million USD | 165.4% |
| 2016 Q4 | -8.26 Million USD | 0.28% |
| 2016 Q1 | -7.32 Million USD | -37.38% |
| 2016 Q2 | -8.49 Million USD | -16.05% |
| 2016 Q3 | -8.28 Million USD | 2.48% |
| 2016 FY | -32.36 Million USD | -56.62% |
| 2015 Q4 | -5.32 Million USD | 10.77% |
| 2015 Q3 | -5.97 Million USD | -20.82% |
| 2015 Q2 | -4.94 Million USD | -11.83% |
| 2015 Q1 | -4.42 Million USD | 17.46% |
| 2015 FY | -20.66 Million USD | 1.59% |
| 2014 Q3 | -6.59 Million USD | -21.02% |
| 2014 FY | -20.99 Million USD | 0.77% |
| 2014 Q1 | -3.6 Million USD | 29.26% |
| 2014 Q4 | -5.35 Million USD | 18.78% |
| 2014 Q2 | -5.44 Million USD | -51.25% |
| 2013 Q4 | -5.09 Million USD | 10.95% |
| 2013 Q3 | -5.71 Million USD | -10.88% |
| 2013 Q2 | -5.15 Million USD | 0.73% |
| 2013 Q1 | -5.19 Million USD | 7.1% |
| 2013 FY | -21.16 Million USD | -231.8% |
| 2012 FY | 16.05 Million USD | 185.16% |
| 2012 Q1 | 30.81 Million USD | 1527.05% |
| 2012 Q2 | -4.35 Million USD | -114.13% |
| 2012 Q3 | -4.8 Million USD | -10.45% |
| 2012 Q4 | -5.59 Million USD | -16.31% |
| 2011 Q3 | -5.01 Million USD | 5.16% |
| 2011 FY | -18.85 Million USD | 20.9% |
| 2011 Q4 | -2.15 Million USD | 56.94% |
| 2011 Q1 | -6.39 Million USD | -3.56% |
| 2011 Q2 | -5.28 Million USD | 17.3% |
| 2010 Q4 | -6.17 Million USD | -31.59% |
| 2010 Q2 | -6.33 Million USD | 4.51% |
| 2010 Q3 | -4.69 Million USD | 25.96% |
| 2010 Q1 | -6.63 Million USD | 23.18% |
| 2010 FY | -23.83 Million USD | 23.36% |
| 2009 Q2 | -7.6 Million USD | 13.84% |
| 2009 Q3 | -5.6 Million USD | 26.24% |
| 2009 Q4 | -8.63 Million USD | -54.01% |
| 2009 FY | -31.09 Million USD | 32.11% |
| 2009 Q1 | -8.82 Million USD | 52.55% |
| 2008 Q2 | -8.66 Million USD | -9.55% |
| 2008 Q4 | -18.59 Million USD | -95.85% |
| 2008 Q3 | -9.49 Million USD | -9.62% |
| 2008 Q1 | -7.9 Million USD | -13.07% |
| 2008 FY | -45.8 Million USD | -86.66% |
| 2007 Q4 | -6.99 Million USD | 10.89% |
| 2007 Q3 | -7.84 Million USD | -1076.76% |
| 2007 Q1 | -9.03 Million USD | 9.92% |
| 2007 Q2 | -667 Thousand USD | 92.61% |
| 2007 FY | -24.54 Million USD | 21.93% |
| 2006 FY | -31.43 Million USD | -101.15% |
| 2006 Q1 | -6.08 Million USD | -2.86% |
| 2006 Q2 | -6.49 Million USD | -6.69% |
| 2006 Q3 | -8.83 Million USD | -35.97% |
| 2006 Q4 | -10.02 Million USD | -13.53% |
| 2005 Q4 | -5.91 Million USD | -199.34% |
| 2005 Q2 | -2.94 Million USD | 38.63% |
| 2005 FY | -15.62 Million USD | 35.71% |
| 2005 Q1 | -4.79 Million USD | 20.83% |
| 2005 Q3 | -1.97 Million USD | 32.78% |
| 2004 FY | -24.3 Million USD | -14.24% |
| 2004 Q3 | -6.46 Million USD | 2.19% |
| 2004 Q1 | -5.18 Million USD | -15.72% |
| 2004 Q4 | -6.05 Million USD | 6.36% |
| 2004 Q2 | -6.6 Million USD | -27.51% |
| 2003 Q1 | -6.01 Million USD | 31.31% |
| 2003 FY | -21.27 Million USD | 45.4% |
| 2003 Q4 | -4.47 Million USD | 18.34% |
| 2003 Q3 | -5.48 Million USD | -3.39% |
| 2003 Q2 | -5.3 Million USD | 11.73% |
| 2002 Q3 | -9.4 Million USD | 9.85% |
| 2002 Q2 | -10.43 Million USD | -0.56% |
| 2002 Q1 | -10.37 Million USD | 4.25% |
| 2002 FY | -38.96 Million USD | 21.12% |
| 2002 Q4 | -8.75 Million USD | 6.98% |
| 2001 Q4 | -10.83 Million USD | -9.06% |
| 2001 Q3 | -9.93 Million USD | 55.21% |
| 2001 Q2 | -22.18 Million USD | -244.52% |
| 2001 Q1 | -6.44 Million USD | 3.48% |
| 2001 FY | -49.4 Million USD | -116.46% |
| 2000 Q3 | -6.17 Million USD | -23.71% |
| 2000 Q1 | 541 Thousand USD | 0.0% |
| 2000 FY | -22.82 Million USD | -143.86% |
| 2000 Q2 | -4.99 Million USD | -1022.37% |
| 2000 Q4 | -6.67 Million USD | -8.08% |
| 1999 FY | -9.35 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 122.091% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1366.434% |
| Embecta Corp. | 221.5 Million USD | 116.652% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 142.069% |
| PainReform Ltd. | -9.58 Million USD | -284.85% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -670.777% |
| SCYNEXIS, Inc. | 72.66 Million USD | 150.756% |
| Journey Medical Corporation | -2.07 Million USD | -1679.257% |
| Safety Shot Inc | -12.18 Million USD | -202.721% |
| Alpha Teknova, Inc. | -35.56 Million USD | -3.715% |
| Bright Green Corporation | -8.89 Million USD | -314.829% |
| Procaps Group, S.A. | 38.97 Million USD | 194.64% |
| Alvotech | -354.86 Million USD | 89.606% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 178.525% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -144.233% |
| Cosmos Health Inc. | -21.83 Million USD | -68.951% |
| Dynavax Technologies Corporation | -37.02 Million USD | 0.389% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 76.29% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 76.858% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -670.777% |
| Theratechnologies Inc. | -10.62 Million USD | -247.078% |
| Harrow Health, Inc. | 580 Thousand USD | 6459.31% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -684.599% |
| Biofrontera Inc. | -22.67 Million USD | -62.649% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -600.019% |
| Cronos Group Inc. | -81.37 Million USD | 54.674% |
| OptiNose, Inc. | -22.74 Million USD | -62.142% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 117.645% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 5.795% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 391.989% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 394.483% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -750.584% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -493.867% |
| Radius Health, Inc. | -3.92 Million USD | -839.72% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -945.828% |
| ProPhase Labs, Inc. | -21.61 Million USD | -70.657% |
| Phibro Animal Health Corporation | 53.31 Million USD | 169.181% |
| Procaps Group S.A. | 52.32 Million USD | 170.492% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -332.758% |
| Viatris Inc. | 766.2 Million USD | 104.814% |
| Rockwell Medical, Inc. | -6.67 Million USD | -452.984% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -602.018% |
| SIGA Technologies, Inc. | 83.62 Million USD | 144.108% |
| Tilray Brands, Inc. | -174.74 Million USD | 78.893% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 495.285% |
| Shineco, Inc. | -17.06 Million USD | -116.127% |
| PetIQ, Inc. | 60.01 Million USD | 161.458% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -678.681% |
| Incannex Healthcare Limited | -30.04 Million USD | -22.779% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 114.701% |
| Alimera Sciences, Inc. | -1.47 Million USD | -2407.41% |
| Silver Spike Investment Corp. | 7.34 Million USD | 602.499% |
| Assertio Holdings, Inc. | -243.53 Million USD | 84.855% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -525.961% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -170.86% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -136.527% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -83.96% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 73.243% |
| Hempacco Co., Inc. | -8.81 Million USD | -318.552% |
| Talphera, Inc. | -16.88 Million USD | -118.391% |
| Alvotech | -354.86 Million USD | 89.606% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 169.001% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 110.115% |
| Currenc Group, Inc. | -6.64 Million USD | -454.998% |
| Kamada Ltd. | 10.06 Million USD | 466.494% |
| Indivior PLC | -4 Million USD | -822.1% |
| Evoke Pharma, Inc. | -7.43 Million USD | -396.36% |
| Flora Growth Corp. | -50.35 Million USD | 26.751% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -83.96% |
| Evolus, Inc. | -49.23 Million USD | 25.083% |
| HUTCHMED (China) Limited | 18.37 Million USD | 300.729% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 118.724% |
| Akanda Corp. | -10.05 Million USD | -266.955% |